AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report

[1]  Kp Suresh.  An overview of randomization techniques: An unbiased assessment of outcome in clinical research , 2011, Journal of human reproductive sciences.

[2]  Qi Zhang,et al.  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.

[3]  H. Dombret,et al.  Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia patients treated in the ALFA0701 trial. , 2019, Blood.

[4]  C. Bloomfield,et al.  Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. , 2019, Blood.

[5]  G. Salles,et al.  Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience , 2019, Cancers.

[6]  M. Yao,et al.  Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients , 2019, EBioMedicine.

[7]  M. Konopleva,et al.  Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes , 2018, Cancer.

[8]  Jian Li,et al.  Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients , 2018, Cancer Cell International.

[9]  Stanley W. K. Ng,et al.  The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia , 2018, Leukemia.

[10]  L. Möllgård,et al.  Acute myeloid leukemia in very old patients , 2018, Haematologica.

[11]  T. Naoe,et al.  Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. , 2018, Leukemia research.

[12]  C. Bloomfield,et al.  Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies , 2018, Leukemia.

[13]  J. Radich,et al.  Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. , 2017, Biopreservation and biobanking.

[14]  Karl W. Kroll,et al.  The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia , 2017, Leukemia.

[15]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[16]  Claude Preudhomme,et al.  A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.

[17]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[18]  W. Hiddemann,et al.  Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. , 2016, Blood.

[19]  K. Stoeber,et al.  Cell cycle status in AML blast cells from peripheral blood, bone marrow aspirates and trephines and implications for biological studies and treatment , 2016, British journal of haematology.

[20]  B. Ko,et al.  Genetic alterations and their clinical implications in older patients with acute myeloid leukemia , 2016, Leukemia.

[21]  X. Ke,et al.  High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia , 2016, Oncotarget.

[22]  Chieh-Yu Liu,et al.  Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia , 2016, Oncotarget.

[23]  Chun Hang Au,et al.  Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms , 2016, Diagnostic Pathology.

[24]  W. Hiddemann,et al.  A 4‐gene expression score associated with high levels of Wilms Tumor‐1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia , 2015, British journal of haematology.

[25]  E. Estey,et al.  Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Colin Campbell,et al.  An integrative approach to predicting the functional effects of non-coding and coding sequence variation , 2015, Bioinform..

[27]  Georgina L Ryland,et al.  A simple consensus approach improves somatic mutation prediction accuracy , 2013, Genome Medicine.

[28]  M. Caligiuri,et al.  A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia , 2013, Leukemia.

[29]  R. Larson,et al.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.

[30]  Thomas M. Schmitt,et al.  Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. , 2012, Blood.

[31]  M. Caligiuri,et al.  Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. , 2011, Blood.

[32]  M. Gobbi,et al.  WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia , 2011, Leukemia & lymphoma.

[33]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[34]  Veronika Rockova,et al.  Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. , 2011, Blood.

[35]  M. Caligiuri,et al.  BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.

[36]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[37]  M. Caligiuri,et al.  Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  H. Gundacker,et al.  Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia , 2010, British journal of haematology.

[39]  E. Thiel,et al.  High correlation of the proteome patterns in bone marrow and peripheral blood blast cells in patients with acute myeloid leukemia , 2009, Journal of Translational Medicine.

[40]  F. Appelbaum.  What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)? , 2008, Best practice & research. Clinical haematology.

[41]  C. Bloomfield,et al.  High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. , 2008, Blood.

[42]  Soheil Meshinchi,et al.  Identification of genes with abnormal expression changes in acute myeloid leukemia , 2008, Genes, chromosomes & cancer.

[43]  J. Radich,et al.  Clinical implications of FLT3 mutations in pediatric AML. , 2006, Blood.

[44]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[45]  C. Bloomfield,et al.  BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  C. Peschle,et al.  Interleukin-3 receptor in acute leukemia , 2004, Leukemia.

[47]  S. Tomoyasu,et al.  Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival , 2003, British journal of haematology.

[48]  F. Appelbaum,et al.  Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. , 2002, Blood.

[49]  G. Ehninger,et al.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. , 2002, Blood.

[50]  J. Radich,et al.  FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. , 2001, Blood.

[51]  F. Appelbaum,et al.  A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). , 1998, Blood.

[52]  M. Reuss-Borst,et al.  AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. , 1994, Leukemia.

[53]  J. Henzen.  Publisher's note , 1979, Brain Research.

[54]  K. Döhner,et al.  Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[56]  J. Esteve,et al.  Treatment of elderly patients with AML: results of an individualized approach. , 1998, Haematologica.

[57]  F. Appelbaum,et al.  A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). , 1998, Blood.

[58]  R. Hornung,et al.  Estimation of Average Concentration in the Presence of Nondetectable Values , 1990 .